基因编辑肠道细菌在结直肠癌治疗中的研究进展

刘印聪1; 2; 张玉亭2; 王一岚2; 刘敏2; 王文学2; 耿嘉蔚2

doi:10.3969/j.issn.1673-6184.2023.02.008

PDF(1702 KB)

微生物与感染 ›› 2023, Vol. 18 ›› Issue (2) : 115-122. DOI: 10.3969/j.issn.1673-6184.2023.02.008

综述

基因编辑肠道细菌在结直肠癌治疗中的研究进展

刘印聪^{1, 2}，张玉亭²，王一岚²，刘敏²，王文学²，耿嘉蔚²

作者信息 +

Research progress on gene-edited intestinal bacteria in the treatment of colorectal cancer

LIU Yincong^{1, 2}, ZHANG Yuting², WANG Yilan², LIU Min², WANG Wenxue², GENG Jiawei²

Author information +

文章历史 +

摘要

结直肠癌(colorectal cancer，CRC)是我国常见的消化道恶性肿瘤。大量研究证实，肠道菌群紊乱可通过多种机制促进CRC的发生、发展，以调节肠道菌群为目的的治疗方式可能对辅助治疗CRC有一定的效果，但仍存在局限性和不良反应。有研究表明，采用基因编辑工程菌与基因编辑直接改造肠道细菌2种方式治疗CRC，具有潜在的临床应用价值。本文通过梳理现阶段基因编辑肠道细菌治疗CRC的相关研究进展，探讨了未来基因编辑肠道细菌治疗CRC的可能性。

Abstract

Colorectal cancer (CRC) is a common digestive malignant tumor in China. A large number of studies have confirmed that intestinal flora disorders can promote the occurrence and development of CRC through a variety of mechanisms, and regulating intestinal flora can exert certain auxiliary therapeutic effects on CRC. But the treatment still has certain limitations and side effects. Studies have shown that the clinical treatment of CRC by engineered and edited intestinal bacteria through gene editing may have potential application values. In this paper, the current research progress on gene-editing for modifying intestinal bacteria in the treatment of CRC is reviewed, aiming to explore the possibility of gene-edited intestinal bacteria in the treatment of CRC in the future.

导出引用

刘印聪1, 2，张玉亭2，王一岚2，刘敏2，王文学2，耿嘉蔚2. 基因编辑肠道细菌在结直肠癌治疗中的研究进展[J]. 微生物与感染. 2023, 18(2): 115-122 https://doi.org/10.3969/j.issn.1673-6184.2023.02.008

LIU Yincong1, 2, ZHANG Yuting2, WANG Yilan2, LIU Min2, WANG Wenxue2, GENG Jiawei2. Research progress on gene-edited intestinal bacteria in the treatment of colorectal cancer[J]. Journal of Microbes and Infections. 2023, 18(2): 115-122 https://doi.org/10.3969/j.issn.1673-6184.2023.02.008

中图分类号： R378 R73